The anti-vascular endothelial growth factor therapeutics global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Anti-Vascular Endothelial Growth Factor Therapeutics Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The anti-vascular endothelial growth factor therapeutics market size has grown marginally in recent years. It will grow from $12.18 billion in 2023 to $12.35 billion in 2024 at a compound annual growth rate (CAGR) of 1.3%. The growth in the historic period can be attributed to rise in age-related macular degeneration, increased incidence of diabetic retinopathy, advancements in retinal disease diagnosis, clinical success and efficacy, shift to outpatient treatment.
The anti-vascular endothelial growth factor therapeutics market size is expected to see marginal growth in the next few years. It will grow to $13.13 billion in 2028 at a compound annual growth rate (CAGR) of 1.5%. The growth in the forecast period can be attributed to aging population and ocular diseases, expanding applications in retinal disorders, development of next-generation therapeutics, increasing emphasis on early intervention, global health initiatives and access to treatment. Major trends in the forecast period include increasing utilization in cancer treatment, focus on combination therapies in ophthalmology, exploration of biosimilar versions, research on resistance mechanisms, integration with imaging technologies.
Order your report now for swift delivery @
Scope Of Anti-Vascular Endothelial Growth Factor Therapeutics Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
Market Drivers –
The increase in the prevalence of ophthalmic diseases is expected to propel the growth of the anti-vascular endothelial growth factor therapeutics market going forward. The prevalence of ophthalmic diseases refers to the number or proportion of individuals within a given population who have been diagnosed with or exhibit specific eye conditions or diseases. Anti-vascular endothelial growth factor (VEGF) therapeutics help reduce the prevalence of ophthalmic diseases by effectively treating ailments such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. For instance, in October 2022, according to World Health Organization, a Switzerland-based international public health organization, globally, around 2.2 billion people have near or distance vision impairment, and 1 billion people suffer from near or distance vision impairment. Further, among these, 88.4 million are suffering from refractive error, 94 million have cataracts, 8 million have age-related macular degeneration, and around 3.9 million have diabetic retinopathy. Therefore, the increase in the prevalence of ophthalmic diseases is driving the growth of the anti-vascular endothelial growth factor therapeutics market.
Market Trends –
Advancements in therapeutics are a key trend gaining popularity in the anti-vascular endothelial growth factor therapeutics market. Companies operating in the anti-vascular endothelial growth factor therapeutics market are adopting advanced therapeutics to sustain their position in the market. For instance, in May 2022, Ashvattha Therapeutics Inc, a US-based clinical-stage biopharmaceutical company, released phase 1 safety data for healthy subjects for subcutaneous anti-VEGF wet AMD (age-related macular degeneration) and DME (diabetic macular edema) candidates. D-4517.2 therapy is a first-in-class therapy developed to address the unmet needs of DME conditions. D-4517.2 therapy is being developed for self-administration using an autoinjector. The autoinjector D-4517.2 enable patients to self-administer the medication once a month in the comfort of their home.
The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –
1) By Product: Eylea, Lucentis, Beovu
2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users
Get an inside scoop of the anti-vascular endothelial growth factor therapeutics market, Request now for Sample Report @
Regional Insights –
North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2023. Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Key Companies –
Major companies operating in the anti-vascular endothelial growth factor therapeutics market report are F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., Coherus BioSciences Inc., Applied Molecular Genetics Inc., Eli Lilly and Company, Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc, Allergan Inc., Novartis AG, kyowa Kirin Co. Ltd., Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc.
Table of Contents
1. Executive Summary
2. Anti-Vascular Endothelial Growth Factor Therapeutics Market Report Structure
3. Anti-Vascular Endothelial Growth Factor Therapeutics Market Trends And Strategies
4. Anti-Vascular Endothelial Growth Factor Therapeutics Market – Macro Economic Scenario
5. Anti-Vascular Endothelial Growth Factor Therapeutics Market Size And Growth
…..
27. Anti-Vascular Endothelial Growth Factor Therapeutics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
Twitter: https://twitter.com/tbrc_info
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
